Afimoxifene

Afimoxifene (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.

Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.